Liraglutide
Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid
Novo Nordisk · Phase 3 · Terminated · Enrollment 2
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| GLP-1 (Liraglutide) | n/r | n/r | n/r | n/r |
| Placebo Comparator | n/r | n/r | n/r | n/r |
Not shown
- GLP-1 (Liraglutide): endpoint not reported
- Placebo Comparator: endpoint not reported